Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infection

The study

A monocentric pilot longitudinal observational study was conducted on 114 participants, who had tested positive by real-time quantitative polymerase chain reaction (RT-PCR) for SARS-CoV-2 in the period between 1-30 March 2020. Written informed consent was obtained by all participants for voluntary participation in this study.The demographic characteristics, blood groups, co-morbidities, clinical features, treatment undertaken, and dates pertaining to symptom onset and RT-PCR tests were recorded. Sequential serum samples were collected over a period of ten months through six serial blood tests at appropriate intervals for 30 out of the 114 subjects who attended all the follow-up visits.

The aim of this study was to investigate for presence and persistency of SARS-CoV-2 specific antibodies over ten months using two commercial immunoassays :The MAGLUMI® 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) Assay (4) for the first five tests and MAGLUMI® SARS-CoV-2 S-RBD IgG Chemiluminescence immunoassay (CLIA) for the last test. (5) These immunoassays were granted Emergency Use Authorization by the US Food and Drug Administration. Measurements and interpretation of results were made according to the manufacturer’s instructions. The subjects were divided into two groups based on disease severity: mild and moderately-severe. (6) Results were reported as measured chemiluminescence values divided by the cut off (absorbance/cut-off, S/CO): S/CO>1 was defined as positive and S/CO≤1 as negative. We treated time as a factor and defined six different time points; T0-T5; first blood sample was collected two months post-infection, in the month of May 2020 (T0) and then, one month (T1), three months (T2), five months (T3), six months (T4) and eight months (T5) after T0. The Association Naso Sano ethical committee approved the study (ANS-2020/001).

Statistical analysis

Descriptive statistics for the main characteristics of the participants were expressed as Median, [1st-3rd] quartile for the continuous variables and as absolute frequency (column percentage) for the categorical variables. CLIA positivity cut-off was set at >1.01. Bar graph was used to determine the percentage of IgM and IgG positivity at each time point. In addition, a sub-analysis was performed dividing the sample into two severity groups (Mild and Moderately-Severe). Chi-squared test was used to measure the association between the severity groups and the categorical variables. The Mann U Whitney test was used to assess the differences between groups for the continuous variables at each time point. Shapiro Wilks tested the normal distribution of the data. The Friedman test was applied to look for statistically significant differences over time within the two severity groups for both IgM and IgG. All tests were two-sided, and a level of statistical significance was set at p<0.05. All the statistical analyses were performed using R software environment for statistical computing and graphics version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria;https://www.R-project.org/)

Results

The data from 30 participants who had tested positive for SARS-CoV-2 infection were analyzed. The descriptive statistics for the main characteristics of the study group are reported in Table 1. The IgM and IgG titres divided into Mild (n=17) and Moderately-severe groups (n=13), expressed as a median [1st – 3rd] are reported in Table 2. Indeed, the p-value results from the Mann U-Whitney test. The CLIA positivity limit was set at >1.01 and the percentage of IgM and IgG positive subjects were analyzed over time, expressed as Bar plots. Anti-S-RBD IgG was detected in 19 out of 30 participants (63.3%) at T5, ten months post-infection. [Figure1].

• Download figure
• Open in new tab

Figure 1.

Bar plot for IgM and IgG positivity over ten months for all participants (n=30). (CLIA cut-off >1.10). B; Baseline, T0-T5 are the six sequential serological test time points.

The titres were higher for the female participants throughout the duration of 10 months (7, 5 and 2 females with 100%, 83.3% and 66.6% IgG positivity respectively Vs 7, 0 and 1 male with 100%, 83.3% and 66.6% IgG positivity respectively). Box plot diagrams for IgM and IgG for Mild (Panel 2A, Panel 2B) and Moderately-Severe (Panel 2C, Panel 2D) groups respectively are reported in Figure 2. For both groups, the IgM titre trend stayed below the set cut-off throughout time and also within the groups, changed in a statistically significant way (p<0.001). The IgG titre trend for both groups stayed above the positivity cut-off over time but did not change in a statistically significant way. (Mild: p=0.310, Moderately-Severe: p=0.370).

• Download figure
• Open in new tab

Figure 2.

Friedman test for repeated measurements for IgG and IgM. Panel 2A and 2B are for the Moderately-Severe group (n=13) and Panel 2C and 2D are for the Mild group (n=17) (shaded as pale yellow). Pairwise comparisons have the following significance codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’

Discussion

SARS-CoV-2 is an enveloped beta-coronavirus with four structural proteins: Spike (S) protein, membrane (M) protein, envelope (E) protein and nucleocapsid (N) protein. Among the four proteins, the S protein and N protein are the main immunogens. The S protein is responsible for eliciting a highly potent neutralizing antibody response and is comprised of an N-terminal S1-subunit for virus-receptor binding and a C terminal S2-subunit for virus-cell membrane fusion. The S1-subunit is further divided into an N terminal domain (NTD) and a receptor-binding domain (RBD). This RBD directly interacts with host receptors to gain cell entry and is the most critical target for SARS-Cov-2 neutralizing Antibodies(nAb). (7,8) Antibodies against S protein can be detected six days post-PCR confirmation of infection, and those directed against the spike RBD show neutralizing capacity and could “prevent infection”. (9,10)

Recent study by Ibarrondo et al. have raised concerns regarding the duration of immunity offered by these antibodies. (11) Following this, Long et al. argued that “rapidly waning immunity” may lead to a substantial number of false-negative immunoassay results. (8) In contrast to these observations, some studies demonstrated the detection of antigen-specific memory T cells and memory B (Bmem) cells during convalescence. (12,13) Hartley et al. used unique sets of fluorescently-labeled recombinant tetramers of SARS-CoV-2 RBD and NCP antigens to “extensively characterize” the SARS-CoV-2-specific B mem cell response. The presence of circulating RBD- and NCP-specific Bmem cell subsets were detected early post-infection and persisted over 242 days post-symptom onset. These results also demonstrated that a decline in serum antibodies during the convalescent period might not reflect the waning of immunity, but rather a “contraction of the immune response” with “development and persistence of B cell memory”. (14)

An important point needs to be highlighted in terms of the association between humoral immune response and disease severity. A study by Choe et al. demonstrated that patients who might have experienced a relatively severe infection may develop an immunity that persists for a longer duration. (3) Similar results were observed in our study.

Conclusion

The strengths of our study include diverse sample quality involving multiple family clusters of different age groups from the same region, adoption of CLIA as the method for analyzing the antibody titres and a long-term follow-up of 10 months post-infection. In a systematic review and meta-analysis by Bastos et al., pooled sensitivity with CLIA was 97.8% as compared to 84.3% with ELISA. (15) Our study reported zero cases of re-infection despite the fact that the Umbria region currently is experiencing a surge in daily cases with mutant strains.